- Report
- December 2022
- 123 Pages
Asia Pacific
From €1345EUR$1,500USD£1,149GBP
- Report
- December 2022
- 106 Pages
North America
From €1345EUR$1,500USD£1,149GBP
- Report
- October 2021
- 288 Pages
Global
From €3228EUR$3,600USD£2,758GBP
- Report
- March 2025
- 99 Pages
Global
From €3500EUR$4,182USD£3,095GBP
- Drug Pipelines
- March 2023
- 125 Pages
Global
From €13445EUR$14,995USD£11,488GBP
The Colitis Drug market is a subset of the Gastrointestinal Drugs market, which includes drugs used to treat a variety of gastrointestinal disorders. Colitis drugs are used to treat inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. These drugs are typically administered orally or intravenously, and can include corticosteroids, immunomodulators, and biologics. Corticosteroids are used to reduce inflammation, while immunomodulators are used to suppress the immune system and reduce inflammation. Biologics are used to target specific proteins in the body that are involved in the inflammatory process.
Some companies in the Colitis Drug market include AbbVie, Amgen, AstraZeneca, Janssen, Merck, Pfizer, and Takeda. Show Less Read more